Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
GSK269962A at concentration of 50nM could dramatically inhibit basal myometrial contraction at 72h and abolish the procontractile effect of LPS
is a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth
is a selective VEGFR1 inhibitor
24)13-6-3-11(9-21-13)15(17
InChi: InChI=1S/C18H26N2O2/c1-14(2)17(18(22)20-12-6-7-13-20)19-16(21)11-10-15-8-4-3-5-9-15/h3-5
LEE011 succinate hydrate(1:1:x) Catalog No.:M9046-2 GSK269962A at concentration of 50nMLEE011 succinate hydrate is an orally available cyclin dependent kinase (CDK) inhibitor targeting cyclin D1 CDK4 and cyclin D3 CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4 6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK mediated G1 S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing
US$ 19.95
US$ 37.00
US$ 17.95